Does Zydus’ Promising CAPS Candidate Have An Edge Over Novartis’ Ilaris?
Potential In Chronic Inflammatory Diseases
Executive Summary
Zydus has established proof of concept for ZYIL1, a NLRP3 inflammasome inhibitor to treat cryopyrin-associated periodic syndromes, via Phase II trials in Australia. Will the oral drug have an upper hand over injectables like Novartis’ Ilaris?